Morrison, L., Loibl, S. & Turner, N. C. The CDK4/6 inhibitor revolution—a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89–105 (2024).

Article  CAS  PubMed  Google Scholar 

Hortobagyi, G. N. et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann. Oncol. 36, 149–157 (2025).

Article  CAS  PubMed  Google Scholar 

O’Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 8, 1390–1403 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174–1193 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong, X. et al. Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell 32, 761–776 (2017).

Article  CAS  PubMed  Google Scholar 

Kudo, R. et al. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell 42, 1919–1935 (2024).

Article  CAS  PubMed  Google Scholar 

Petroni, G., Buque, A., Zitvogel, L., Kroemer, G. & Galluzzi, L. Immunomodulation by targeted anticancer agents. Cancer Cell 39, 310–345 (2021).

Article  CAS  PubMed  Google Scholar 

Petroni, G., Formenti, S. C., Chen-Kiang, S. & Galluzzi, L. Immunomodulation by anticancer cell cycle inhibitors. Nat. Rev. Immunol. 20, 669–679 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uzhachenko, R. V. et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 35, 108944 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitt, C. A., Wang, B. & Demaria, M. Senescence and cancer—role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 19, 619–636 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peuker, C. A. et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial. Eur. J. Cancer 162, 45–55 (2022).

Article  CAS  PubMed  Google Scholar 

Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356–371 (2019).

Article  CAS  PubMed  Google Scholar 

Ali, L. R. et al. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. J. Exp. Med. 220, e20220729 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan, Y. et al. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur. J. Cancer 154, 11–20 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petroni, G. et al. Radiotherapy delivered before CDK4/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer. Clin. Cancer Res. 27, 1855–1863 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C. & Galluzzi, L. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat. Rev. Clin. Oncol. 19, 114–131 (2022).

Article  CAS  PubMed  Google Scholar 

Petroni, G., Buqué, A., Coussens, L. M. & Galluzzi, L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug Discov. 21, 440–462 (2022).

Article  CAS  PubMed  Google Scholar 

De Angelis, C. et al. Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER+ breast cancer. Clin. Cancer Res. 27, 4870–4882 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Teh, J. L. F. & Aplin, A. E. Arrested developments: CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clin. Cancer Res. 25, 921–927 (2019).

Article  CAS  PubMed  Google Scholar 

Buque, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alamilla-Presuel, J. C., Burgos-Molina, A. M., González-Vidal, A., Sendra-Portero, F. & Ruiz-Gómez, M. J. Factors and molecular mechanisms of radiation resistance in cancer cells. Int. J. Radiat. Biol. 98, 1301–1315 (2022).

Article  CAS  PubMed  Google Scholar 

Beringer, A. & Miossec, P. Systemic effects of IL-17 in inflammatory arthritis. Nat. Rev. Rheumatol. 15, 491–501 (2019).

Article  PubMed  Google Scholar 

Gelderblom, H. et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer 127, 884–893 (2021).

Article  CAS  PubMed  Google Scholar 

Buque, A. et al. Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis. J. Natl Cancer Inst. 117, 934–947 (2025).

Article  PubMed  Google Scholar 

Buqué, A. & Galluzzi, L. Modeling tumor immunology and immunotherapy in mice. Trends Cancer 4, 599–601 (2018).

Article  PubMed  Google Scholar 

Rugo, H. S. et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin. Cancer Res. 24, 2804–2811 (2018).

Article  CAS  PubMed  Google Scholar 

Petroni, G. & Galluzzi, L. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. Oncoimmunology 10, 1889101 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Guo, S., Jiang, X., Mao, B. & Li, Q. X. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer 19, 718 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Heckler, M. et al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov. 11, 2564–2581 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teh, J. L. F. et al. Activation of CD8+ T cells contributes to antitumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer Immunol. Res. 8,